Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 93

Related Citations for PubMed (Select 23997927)

1.

Aliskiren: review of efficacy and safety data with focus on past and recent clinical trials.

Sen S, Sabırlı S, Ozyiğit T, Uresin Y.

Ther Adv Chronic Dis. 2013 Sep;4(5):232-41. doi: 10.1177/2040622313495288.

2.

[The future of renin inhibition].

Uresin AY, Baran E.

Turk Kardiyol Dern Ars. 2009 Oct;37 Suppl 7:32-8. Turkish.

PMID:
20019475
3.
4.

[Direct renin inhibitor aliskiren in the treatment of cardiovascular and renal diseases].

Horký K.

Vnitr Lek. 2010 Feb;56(2):120-6. Review. Czech.

PMID:
20329582
5.

Managing cardiovascular and renal risk: the potential of direct renin inhibition.

Sever PS, Gradman AH, Azizi M.

J Renin Angiotensin Aldosterone Syst. 2009 Jun;10(2):65-76. doi: 10.1177/1470320309104662. Review.

PMID:
19502253
6.

Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy.

Solomon SD, Appelbaum E, Manning WJ, Verma A, Berglund T, Lukashevich V, Cherif Papst C, Smith BA, Dahlöf B; Aliskiren in Left Ventricular Hypertrophy (ALLAY) Trial Investigators.

Circulation. 2009 Feb 3;119(4):530-7. doi: 10.1161/CIRCULATIONAHA.108.826214. Epub 2009 Jan 19.

7.

New class of agents for treatment of hypertension: focus on direct renin inhibition.

Fogari R, Zoppi A.

Vasc Health Risk Manag. 2010 Oct 5;6:869-82. doi: 10.2147/VHRM.S4189. Review.

8.

Aliskiren: an oral direct renin inhibitor for the treatment of hypertension.

Sanoski CA.

Pharmacotherapy. 2009 Feb;29(2):193-212. doi: 10.1592/phco.29.2.193. Review.

PMID:
19170589
9.

Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study.

Krum H, Massie B, Abraham WT, Dickstein K, Kober L, McMurray JJ, Desai A, Gimpelewicz C, Kandra A, Reimund B, Rattunde H, Armbrecht J; ATMOSPHERE Investigators.

Eur J Heart Fail. 2011 Jan;13(1):107-14. doi: 10.1093/eurjhf/hfq212.

PMID:
21169387
10.

Safety and efficacy of aliskiren in the treatment of hypertension and associated clinical conditions.

Angeli F, Reboldi G, Mazzotta G, Poltronieri C, Garofoli M, Ramundo E, Biadetti A, Verdecchia P.

Curr Drug Saf. 2012 Feb;7(1):76-85. Review.

PMID:
22663961
11.

Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy?

Werner C, Pöss J, Böhm M.

Drugs. 2010 Jul 9;70(10):1215-30. doi: 10.2165/11537910-000000000-00000. Review.

PMID:
20568830
12.

Aliskiren: renin inhibitor for hypertension management.

Cheng JW.

Clin Ther. 2008 Jan;30(1):31-47. doi: 10.1016/j.clinthera.2008.01.011. Review.

PMID:
18343241
13.
14.

Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan.

Pool JL, Schmieder RE, Azizi M, Aldigier JC, Januszewicz A, Zidek W, Chiang Y, Satlin A.

Am J Hypertens. 2007 Jan;20(1):11-20.

PMID:
17198906
15.

Clinical pharmacokinetics and pharmacodynamics of aliskiren.

Vaidyanathan S, Jarugula V, Dieterich HA, Howard D, Dole WP.

Clin Pharmacokinet. 2008;47(8):515-31. Review.

PMID:
18611061
16.

Cardiovascular risk in hypertension - can we ask for more? : focus on aliskiren.

Volpe M.

High Blood Press Cardiovasc Prev. 2008 Oct;15(4):255-68. doi: 10.2165/0151642-200815040-00005. Epub 2013 Jan 22.

PMID:
23355128
17.

Current strategies to achieve further cardiac and renal protection through enhanced renin-angiotensin-aldosterone system inhibition.

Alfie J, Aparicio LS, Waisman GD.

Rev Recent Clin Trials. 2011 May;6(2):134-46. Review.

PMID:
21241234
18.

Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure.

McMurray JJ, Pitt B, Latini R, Maggioni AP, Solomon SD, Keefe DL, Ford J, Verma A, Lewsey J; Aliskiren Observation of Heart Failure Treatment (ALOFT) Investigators.

Circ Heart Fail. 2008 May;1(1):17-24. doi: 10.1161/CIRCHEARTFAILURE.107.740704.

19.

Aliskiren, a direct renin inhibitor, in clinical practice: a new approach in the treatment of hypertension.

Moutzouri E, Florentin M, Elisaf MS, Mikhailidis DP, Liberopoulos EN.

Curr Vasc Pharmacol. 2010 May;8(3):344-62. Review.

PMID:
20180771
20.

Direct inhibition of renin as a cardiovascular pharmacotherapy: focus on aliskiren.

Sepehrdad R, Frishman WH, Stier CT Jr, Sica DA.

Cardiol Rev. 2007 Sep-Oct;15(5):242-56. Review.

PMID:
17700383
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk